Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Istituto Oncologico Veneto IRCCS
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
NRG Oncology
M.D. Anderson Cancer Center
City of Hope Medical Center
Leiden University Medical Center
Emory University
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Emory University
Weill Medical College of Cornell University
Fox Chase Cancer Center
Hospital of Macerata
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
University of Utah
University of Texas Southwestern Medical Center
Centre Francois Baclesse
Gustave Roussy, Cancer Campus, Grand Paris
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Nationwide Children's Hospital
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Centre Leon Berard
Vanderbilt-Ingram Cancer Center
University of Utah
University of Pittsburgh
Columbia University
University of Colorado, Denver
Gustave Roussy, Cancer Campus, Grand Paris
Fundacion CRIS de Investigación para Vencer el Cáncer
Hoosier Cancer Research Network
University of Utah
Icahn School of Medicine at Mount Sinai
Gruppo Oncologico Italiano di Ricerca Clinica
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
University of Utah
OHSU Knight Cancer Institute
Spanish Oncology Genito-Urinary Group
SCRI Development Innovations, LLC
Spanish Oncology Genito-Urinary Group
Duke University
Augusta University
Centre Hospitalier Universitaire de Besancon
M.D. Anderson Cancer Center
Johannes Gutenberg University Mainz
Dana-Farber Cancer Institute